Certain A Shares of APT Medical Inc. are subject to a Lock-Up Agreement Ending on 7-JAN-2022.
January 06, 2022
Share
Certain A Shares of APT Medical Inc. are subject to a Lock-Up Agreement Ending on 7-JAN-2022. These A Shares will be under lockup for 373 days starting from 30-DEC-2020 to 7-JAN-2022.
Details:
Cheng Zhenghui, as the company's controlling shareholder and actual controller, as the company's chairman and general manager, and Cheng Ling as the company's joint actual controller committed that within 36 months since the date of listing of the present shares, there will not be no transfers nor entrustment of shares to any third party nor repurchase by the Company. If, within 6 months after the issuer's listing, the closing price of the shares is lower than issuance price for 20 consecutive trading days or if trading price is lower than issuance price after 6 month from listing, lock-up period will be automatically extended for another 6 months. If there is any case of dividends, bonus shares, capitalization of capital reserve and other similar cases, issue price will be adjusted according to ex-dividend and ex-interests. After the expiry of the lock-up period (including the extended lock-up period), the parties promise that yearly transfer of shares made by them will not exceed 25% of the holding, both direct and indirect, held by the present parties. After 6 months from rescindment, there will not be more transfers of shares, either direct or indirect. If any of the parties were to resign within 6 months from the present IPO, neither direct nor indirect holdings might be transferred or sold for 18 months since the date of rescinding. If the parties resign within 7 to 12 months after the IPO, neither direct nor indirect holdings might be transferred or sold for 12 months since the date of rescinding.
. In addition to the actual controller of the company, Xu Yiqing, Dai Zhenhua, Hu Xubo, Han Yonggui, Gong Lei, Jiang Yachao, Dai Guangrong, Yuchen Qiu, Liu Fangyuan and Wang Wei who directly or indirectly hold the companys shares, controlling shareholders, actual controllers, directors, supervisors or senior management who directly or indirectly hold company shares, other shareholders of the company Qiming Weichuang (Shanghai) Equity Investment Center (Limited Partnership), QM33 LIMITED, Shenzhen Huishen Enterprise Management Center (Limited Partnership), Suzhou Industrial Park Qihua Phase III Investment Center (Limited Partnership), Suzhou Qiming Chuangzhi Equity Investment Partnership (Limited Partnership), Suzhou Industrial Park Qiming Rongke Equity Investment Partnership (Limited Partnership), Nantong Fuxing Enterprise Management Center (Limited Partnership), Yiyixin, Nantong Dongzheng Huixiang Equity Investment Center (Limited Partnership), Cheng Fan, Nantong Dongzheng Fuxiang Equity Investment Center (Limited Partnership), Nantong Huizhen Enterprise Management Center (Limited Partnership), Suzhou Qiming Rongying Venture Investment Partnership (Limited Partnership), Nantong Huishi Enterprise Management Center (Limited Partnership), Nantong Huihui Enterprise Management Center (Limited Partnership) and Huang Zheng, company's core technical staff Han Yonggui, Yuchen Qiu and Zhang Yong promised that wthin 12 months since the date of listing of the present shares, there will not be no transfers nor entrustment of shares to any third party nor repurchase by the Company. If, within 6 months after the issuer's listing, the closing price of the shares is lower than issuance price for 20 consecutive trading days or if trading price is lower than issuance price after 6 month from listing, lock-up period will be automatically extended for another 6 months. If there is any case of dividends, bonus shares, capitalization of capital reserve and other similar cases, issue price will be adjusted according to ex-dividend and ex-interests. After the expiry of the lock-up period (including the extended lock-up period), the parties promise that yearly transfer of shares made by them will not exceed 25% of the holding, both direct and indirect, held by the present parties. After 6 months from rescindment, there will not be more transfers of shares, either direct or indirect. If any of the parties were to resign within 6 months from the present IPO, neither direct nor indirect holdings might be transferred or sold for 18 months since the date of rescinding. If the parties resign within 7 to 12 months after the IPO, neither direct nor indirect holdings might be transferred or sold for 12 months since the date of rescinding.
APT Medical Inc is a China-based company mainly engaged in the research and development, manufacture and sales of electrophysiological and vascular interventional medical devices. The Company's electrophysiological products include electrophysiological electrode catheters, controllable radiofrequency ablation electrode catheters and multichannel electrophysiological systems. Its coronary artery access products mainly include guide wires, micro catheters, balloons, contrast guide wires and catheters. The Company's peripheral vascular intervention products are mainly applied in peripheral vascular diseases. The Company is also engaged in related original equipment manufacturer (OEM) business. The Company distributes its products within domestic market and to overseas markets.